支气管哮喘靶向治疗药物研究进展  

Research progress of targeted drugs for bronchial asthma

作　　者：陈晨[1] 史莹[1] 毛山[1] CHEN Chen;SHI Ying;MAO Shan(Department of Respiratory,Nanjing Hospital Affiliated to Nanjing Medical University,Nanjing 210006,Jiangsu Province,China)

机构地区：[1]南京医科大学附属南京医院呼吸科,江苏南京210006

出　　处：《世界临床药物》2020年第1期1-6,共6页World Clinical Drug

基　　金：南京市医学科技发展杰出青年基金项目(JQX16028).

摘　　要：支气管哮喘是常见的气道慢性炎症性疾病,其临床症状以及对治疗的反应具有异质性。绝大多数患者发作时可通过抗炎、平喘等传统治疗药物得到控制,但仍有部分患者的病情需要借助全身应用高剂量激素才可缓解或仍无法控制,甚至威胁生命。近年来,随着人们对支气管哮喘发病机制和靶向药物研究的不断深入,针对这些难治性重症哮喘,新的药物开始被逐渐应用于临床,并给临床医生带来更多哮喘精准治疗的选择。Bronchial asthma is a common chronic airway inflammatory disease,and its clinical symptoms and treatment responsiveness are heterogeneous.The vast majority of patients can be controlled by traditional treatment drugs such as anti-inflammatory during the onset of asthma,but still some patients need to be relieved with the help of high-dose systemic application of hormones,or still unable to control,or even threaten life.In recent years,with the continuous deepening of research on the pathogenesis of bronchial asthma and targeted drugs,new drugs have gradually begun to be applied to the clinic for these refractory severe asthma,bringing more choices for accurate treatment of asthma to clinicians.

关 键 词：支气管哮喘 靶向药物 治疗 

分 类 号：R562.2[医药卫生—呼吸系统]